Cargando…

EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with “Stop-And-Go” Osimertinib

A 69-year-old man with post-operative recurrence of lung adenocarcinoma was treated with multiple chemotherapies, including epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. A second biopsy revealed an EGFR T790M mutation. As 10th-line chemotherapy, osimertinib was initiated. After...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobayashi, Keigo, Naoki, Katsuhiko, Kuroda, Aoi, Yasuda, Hiroyuki, Kawada, Ichiro, Soejima, Kenzo, Betsuyaku, Tomoko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919862/ https://www.ncbi.nlm.nih.gov/pubmed/29269665 http://dx.doi.org/10.2169/internalmedicine.9609-17

Ejemplares similares

Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer
por: Kobayashi, Keigo, et al.
Publicado: (2018)

Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations
por: Masuzawa, Keita, et al.
Publicado: (2017)

Secondary Brain Neoplasm after Stereotactic Radiosurgery in Patients with Metastatic Non-small Cell Lung Cancer
por: Nukaga, Shigenari, et al.
Publicado: (2018)

Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors
por: Hamamoto, Junko, et al.
Publicado: (2017)

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer
por: Hirano, Toshiyuki, et al.
Publicado: (2015)

Multiple nodular lesions following Pneumocystis pneumonia in a non‐HIV immunocompromised patient
por: Asakura, Takanori, et al.
Publicado: (2016)

A Case of Non-Small Cell Lung Cancer with Possible “Disease Flare” on Nivolumab Treatment
por: Chubachi, Shotaro, et al.
Publicado: (2016)

Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients
por: Yagasaki, Kaori, et al.
Publicado: (2018)

Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells
por: Watanabe, Hideo, et al.
Publicado: (2008)

Intracellular levels of reactive oxygen species correlate with ABT‐263 sensitivity in non‐small‐cell lung cancer cells
por: Ohgino, Keiko, et al.
Publicado: (2020)

Ground-glass opacities accompanied by pulmonary cysts
por: Marchiori, Edson, et al.
Publicado: (2020)

Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinoma
por: Nishino, Makoto, et al.
Publicado: (2017)

Terrien’s Marginal Degeneration Accompanied by Latticed Stromal Opacities
por: Zhang, Yibing, et al.
Publicado: (2014)

Effects of the common polymorphism in the human aldehyde dehydrogenase 2 (ALDH2) gene on the lung
por: Kuroda, Aoi, et al.
Publicado: (2017)

Radiologic features of precancerous areas of the lungs in chronic obstructive pulmonary disease
por: Chubachi, Shotaro, et al.
Publicado: (2017)

Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations
por: Ikemura, Shinnosuke, et al.
Publicado: (2019)

Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study)
por: Morikawa, Kei, et al.
Publicado: (2020)

Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer
por: SATO, TAKASHI, et al.
Publicado: (2015)

Dry pleurisy complicating solitary pulmonary nodules caused by Mycobacterium avium: a case report
por: Asakura, Takanori, et al.
Publicado: (2015)

Methylation-induced downregulation of TFPI-2 causes TMPRSS4 overexpression and contributes to oncogenesis in a subset of non-small-cell lung carcinoma
por: Hamamoto, Junko, et al.
Publicado: (2015)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Tuberous sclerosis diagnosed by incidental computed tomography findings of multifocal micronodular pneumocyte hyperplasia: a case report
por: Ishii, Makoto, et al.
Publicado: (2012)

Inseparability of Go and Stop in Inhibitory Control: Go Stimulus Discriminability Affects Stopping Behavior
por: Ma, Ning, et al.
Publicado: (2016)

Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study
por: Ishikawa, Emi, et al.
Publicado: (2023)

DNA Methylation Profiles at Precancerous Stages Associated with Recurrence of Lung Adenocarcinoma
por: Sato, Takashi, et al.
Publicado: (2013)

Neutrinos stop going West
Publicado: (1998)

Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study
por: Peled, Nir, et al.
Publicado: (2021)

EGFR G796D mutation mediates resistance to osimertinib
por: Zheng, Di, et al.
Publicado: (2017)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation?
por: Iwamoto, Natsuhiko, et al.
Publicado: (2022)

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
por: Lee, Jiyun, et al.
Publicado: (2022)

Edoxaban treatment for pulmonary arterial thromboembolism associated with azygous vein aneurysm
por: Mochimaru, Takao, et al.
Publicado: (2017)

Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR ‐major mutant NSCLC receiving osimertinib
por: Kaira, Kyoichi, et al.
Publicado: (2023)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Single Nodular Opacity of Granulomatous Pneumocystis Jirovecii Pneumonia in an Asymptomatic Lymphoma Patient
por: Kim, Hyun Soo, et al.
Publicado: (2015)

Stop and go L1CAM
por: LeBrasseur, Nicole
Publicado: (2003)

Go and stop signals for glial regeneration
por: Hidalgo, Alicia, et al.
Publicado: (2017)

The economics of stop-and-go epidemic control
por: Gros, Claudius, et al.
Publicado: (2022)

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
por: Murano, Chihiro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_170slg3v12tvq8ms346osg9h18